Funder: National Institutes of Health (NIH)
Due Dates: October 6, 2025 (final application deadline; letter of intent due 30 days prior)
Funding Amounts: Up to $295,924 for Phase I (6 months); up to $1,972,828 for Phase II (2 years); higher budgets may be allowed for approved waiver topics.
Summary: Supports U.S. small businesses developing novel extracellular vesicle-based therapeutic platforms for regenerative medicine, focusing on production, manufacturing, and translation to clinical use.
Key Information: Clinical trials are not allowed; non-U.S. organizations are not eligible to apply.